 | | Vol. 5.43 – 19 November, 2021 |
| |
|
|
| Scientists investigated the role of Sox9, a transcription factor downstream of Yap activation and expressed in biliary epithelial cells, in Yap-induced cell fate plasticity during hepatocarcinogenesis.
[Journal of Hepatology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors identified an oncogenic lncRNA that was upregulated in hepatocellular carcinoma and was transcriptionally induced by TGF-β.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Golgi membrane protein 1 (GOLM1) was positively correlated with infiltrating tumor-associated macrophages expressed high levels of programmed death-ligand 1 (PD-L1) and CD8+ T cell suppression in hepatocellular carcinoma tissues.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Investigators screened a phage display library for peptides that structurally mimicked a sporozoite ligand for hepatocyte recognition.
[Nature Communications] |
|
|
|
| Scientists investigated the role of TM4SF5 in communication between hepatocytes and macrophages and its possible influence on the inflammatory microenvironment that may lead to nonalcoholic fatty liver disease.
[Cell Reports] |
|
|
|
| Researchers showed that copper metabolism MURR1 domain (COMMD)10-deficient Kupffer cells adopted liver-specific identity.
[Cell Reports] |
|
|
|
| TRβ1 and its principal corepressor NCoR1 in hepatocytes repressed de novo lipogenesis, whereas the TH-mediated induction of lipogenic genes depended on the transcription factor ChREBP.
[Science Signaling] |
|
|
|
| Regorafenib preferentially increased the growth inhibition and apoptosis of CK19+ cells in vitro, whereas sorafenib, apatinib, and 5-fluorouracil did not.
[Cell Death & Disease] |
|
|
|
| Investigators implicated that glucosylceramide accumulation was one of the triggers promoting the development of nonalcoholic fatty liver disease into non-alcoholic steatohepatitis, then, fibrosis and tumorigenesis.
[iScience] |
|
|
|
| The authors performed whole-genome sequencing on clonally expanded single liver stem cells cultured as intrahepatic cholangiocyte organoids from patients with alcoholic cirrhosis, non-alcoholic steatohepatitis, and primary sclerosing cholangitis.
[Communications Biology] |
|
|
|
| Researchers discovered that TRAF7 was overexpressed in hepatocellular carcinoma tumor tissues and the increased TRAF7 expression was closely associated with tumor size, histologic grade, TNM stage and poor prognostication.
[Cell Death Discovery] |
|
|
|
| Scientists sampled 175 hepatocellular carcinoma, 117 cirrhotic and 165 non-cirrhotic controls from a prospective cohort study of chronically hepatitis B virus-infected individuals to assess immunologic markers in relation to liver disease.
[Scientific Reports] |
|
|
|
| Researchers contrasted how palmitic acid and oleic acid impacted the morphology and interaction between lipid droplets and mitochondria, and mitochondrial bioenergetics in HepG2 cells.
[Frontiers in Nutrition] |
|
|
|
|
| Investigators provide a description of several key mechanisms that contribute to lipid droplet accumulation in the hepatocytes, favoring non-alcoholic fatty liver disease (NAFLD) progression.
[Journal of Hepatology] |
|
|
|
| The authors summarize the genetics and biochemistry of aldehyde dehydrogenase 2 (ALDH2), the metabolic consequences of ethanol consumption associated with an ALDH2 deficiency, and gene therapy strategies to correct ALDH2 deficiency and its associated cancer risk.
[Cancer Gene Therapy] |
|
|
|
| Scientists discuss the mechanisms that facilitate intracellular fatty-acid mobilization, drawing on canonical and noncanonical enzymatic pathways.
[Nature Metabolism] |
|
|
|
|
| Singapore-based SCG Cell Therapy Pte Ltd has signed an agreement with the Cell Therapy Facility of Singapore Health Sciences Authority for the evaluation of SCG’s proprietary cell therapy manufacturing process to develop a new treatment option for Hepatitis B virus-related hepatocellular carcinoma.
[Singapore Health Sciences Authority] |
|
|
|
| Elevar Therapeutics, Inc. announced that the US FDA has granted rivoceranib with orphan drug designation for the treatment of HCC, the most common primary liver malignancy and is a leading cause of cancer-related death worldwide.
[Elevar Therapeutics, Inc.] |
|
|
|
|
| December 8 – 11, 2021
Geneva, Switzerland |
|
|
|
|
|
| KU Leuven – Leuven, Belgium |
|
|
|
| | Emory University – Atlanta, Georgia, United States |
|
|
|
| | German Research Center for Environmental Health – Oberschleißheim, Germany |
|
|
|
| | Uppsala University – Uppsala, Sweden |
|
|
|
| | King’s College London – London, England, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
